Fin Medium

Industry Overview Industry at large is experiencing operating deleverage in this financial year due to sharp decline in COVID and COVID-related revenue. The decline in COVID business has been to the extent of 80% to 85% compared to last year in general. Industry also experienced tough competitions in these couple of years, entry of many players coming from pharma, hospitals and even e-commerce as well. Most large players in the industry also haven't taken meaningful price increases in the last five to six years.  Bundling of tests may have led to higher realization per patient but has resulted in an effective decline in realization per test. It's very clear in recent trends that patients or consumers are looking for a higher level of convenience. Those days have gone, where people will come to a lab and stand in the queue and wait for 30-35 minutes for their turn to come and give blood samples. So, they are expecting collection to be done near them, which could be in the format

Business Overview LPL is an established consumer healthcare brand in diagnostic services and one of the largest companies offering exposure to this segment within healthcare in India. The foundation of this company was laid in 1949 by Dr. Major S. K. Lal, who is the father of Dr. Lal. LPL operates under a hub and spoke model. This includes LPL’s National Reference Laboratory which is located in New Delhi, supported by 175 clinical laboratories, 1,592 patient service centers and over 7,300 pickup points presently. Under this arrangement, samples are collected across multiple locations within a region and are forwarded to pre-designated clinical laboratories for centralized diagnostic testing. This provides the company greater efficiencies and of course better economies of scale while making available a scalable platform. LPL is networked across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. A key factor which binds the LPL’s operation

The company is in aquaculture business with operation focusing on 2 vertical industries - 1.  Shrimp Feeds (78%) 2.  Shrimp Processing & Export (22%) Shrimp Feed Industry "Shrimp feed is produced in order to meet the nutritional requirements of farmed shrimps. It helps in maintaining the required levels of essential amino acids, vitamins, minerals, fatty acids and other important nutrients. Some of the common ingredients used in shrimp feed include fish and squid meal, lecithin, fish oil, cereal flour and other essential and propriety additives. The use of good quality feed helps in improving the shrimp production, profits, and minimizing the environmental pollution generated from shrimp farming." Indian Shrimp Feed Market Processed Shrimp Industry "Fully grown shrimps are transferred to processing plants for primary processing which involves slicing of shrimp heads and washing. Then undergoes sorting process based on commercially accepted sizes and weights before ha

The company is in diversified agri-business with operation focusing on five verticals - Animal Feed  Crop Protection Palm Oil / Edible Oil Dairy &  Poultry Processed Food Animal Feed Industry "India  currently represents one of the fastest growing animal feed markets in the world. The increasing demand for animal protein and dairy products has resulted in a growing livestock population in  India , which in turn has increased the demand for animal feed. Currently the poultry, aqua and dairy industry accounts for the major share of the Indian animal feed industry. Modern animal feed products are manufactured by carefully selecting and blending ingredients to impart highly nutritional diets that both increase the quality of its end products such as meat, milk, eggs and at the same time maintain the health of the animal." Indian Animal Feed (Poultry, Cattle, Aqua) Market Report 2019 Crop Protection Industry " The importance of pesticides for agriculture is enormous becau

Ipca is among India's top 20 pharmaceutical companies and is in the business of producing & marketing of  (a)  Active pharmaceutical ingredients (API) (b) Drug Intermediates (c) Formulations The company produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules and  its business in India focuses mainly on therapeutic segments like  Cardiovascular, Anti-diabetic, Pain management, Anti-malarial, Anti-bacterial, Anthelmintics, Central nervous system product, Gastrointestinal products, Cough preparations etc.  What is the difference between terms like API, Bulk drugs, Intermediates, Finished Dosage, and Formulations that are common jargons in the Pharmaceutical Industry? API  – Active Pharmaceutical Ingredient – is the basic drug itself with the desired medicinal (pharmaceutical) properties. Also referred to as Bulk Drugs. Intermediates  – Most chemical reactions are stepwise, that is they take more than one elementary step to complete. An API

Cadila Healthcare is one of the leading, innovation driven pharmaceutical companies in India and is in the business of -  Research & Development of New Chemical Entities (NCE) Manufacturing, marketing and selling of finished dosage human formulations Generics /  Branded Generics Specialty Formulations Biosimilars Vaccines Active pharmaceutical ingredients (APIs)  Animal healthcare products Consumer wellness products via its subsidiary  Zydus Wellness Limited New Chemical Entities (NCE) New Chemical Entity (NCE) research is characterized by large expenditures, long timelines especially in the late phases of clinical trials, increasingly stringent regulatory environment and the commercialization related uncertainties. The company is working on cutting edge technologies in different scientific disciplines to discover novel therapeutic agents. It has the capabilities to conduct drug discovery and development from concept to Investigational New Drug (IND) enabling pre-clinical and clini